When the transaction closes, the largest U.S. drugmaker will gain access to Array’s approved treatment for skin cancer as well as its other experimental cancer drugs.
Pfizer is working to diversify its pipeline as its blockbuster pain medication Lyrica gains generic rivals.
Under the agreement, Pfizer will pay $48 per share of Array.
The boards of both companies have approved the deal. When the transaction is finalized, Array’s employees will join Pfizer.
Read the full news release here.
More articles on pharmacy:
Lupin recalls 18,408 bottles of antibiotic in US
Bluebird Bio prices gene therapy at $1.8M
10 hospitals seeking pharmacy leaders
